OptiBiotix Health plc “designer ingredients to modify microbiome”

OptiBiotix Health plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol, diabetes and skin care, has told DirectorsTalk that it will be presenting research data on its microbiome modulators at the Microbiome R&D and Business Collaboration Congress: Asia, in Hong Kong on the 1-2 March 2017. The conference brings together experts in all areas of microbiome research and is recognised around the world as one of theleading conferences for bringing together pharma, biotech, academic institutions and investors who are looking to develop and progress ground-breaking microbiome research into next generation products through partnering.

 

OptiBiotix’s conference abstract and presentation covers research which demonstrates the company’s ability to create designer ingredients which can modify an individual’s microbiome. These studies suggest commercial potential for:-

 

i.     The development of species or genera specific prebiotics which can selectively enhance the growth and health benefits of existing probiotic products. This new product concept, called an OptiBiotic®, has the potential to enhance probiotic health benefits and provide product differentiation in the probiotic market, a market forecast to be worth more than $46.5bn by 2020 (Markets and Markets). 

ii.    Designer ingredients which can modify an individual’s current microbiome to improve health. These ingredients are heat resistant and stable during processing, which creates the opportunity to incorporate low cost, safe, ingredients which modulate specific elements of the microbiome in a wide range of food products.

Commenting, Stephen O’Hara, CEO of OptiBiotix said: “The ability to create designer ingredients which can modify an individual’s microbiome to improve health places OptiBiotix at the forefront of global microbiome research and product development.  I believe we are fast approaching the next stage in the development of the microbiome in healthcare, where scientists have the ability to precision engineer components of the microbiome to prevent, manage and treat many of today’s chronic lifestyle diseases.”

Click to view all articles for the EPIC:
Or click to view the full company profile:
    Facebook
    Twitter
    LinkedIn
    Optibiotix Health Plc

    More articles like this

    Optibiotix Health Plc

    NutraIngredients Awards shortlist announced

    NutraIngredients is pleased to announce the shortlisted finalists for the 2018 edition of the NutraIngredients Awards … with the winners announced at our exclusive awards evening in Geneva on 16th May. The shortlisted finalistsfor the 10

    Optibiotix Health Plc

    OptiBiotix Health plc Launch of Slimbiome® in Nutri-bites®

    OptiBiotix Health plc (LON:OPTI), a life sciences business developing compounds to tackle obesity, and high cholesterol, today announced the launch of its award winning SlimBiome® in Nutri-Bites® with its US partner, Cereal Ingredients (“CII”), at the 2018 Natural

    Optibiotix Health Plc

    OptiBiotix Health PLC OptiBiotix Capital Reorganisation

    OptiBiotix Health plc (LON:OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol, diabetes announced on 28 November 2017 that it intended to seek a cancellation of its share premium account (the “Capital Reduction”) in

    Optibiotix Health Plc

    Optibiotix Health PLC In a Strong Position

    Optibiotix Health PLC (LON:OPTI) Chief Executive Officer Stephen O’Hara talks to tells Proactive Investors about focussing on the commercialisation of their technology across the company’s platforms.

    Optibiotix Health Plc

    Functional weight loss ingredient, SlimBiome brought to US

    OptiBiotix Health PLC (LON:OPTI), a specialist in the development of functional ingredients to modulate the human microbiome, has entered into a manufacturing and supply agreement with Cereal Ingredients. The agreement grants Cereal Ingredients a licence to

    Optibiotix Health Plc

    SlimBiome® – Supporting hunger-free weight management

    Slimbiome® is OptiBiotix’s patented combination of natural ingredients, identified and developed by leading experts in nutrition and metabolism, which supports scientifically substantiated weight loss claims. In independent tests the component ingredients have shown reductions in calorie intake

    Optibiotix Health Plc

    OptiBiotix Health PLC Proposed Directorate Changes

    OptiBiotix Health PLC (LON:OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol, diabetes and skin care, today announced that subject to the completion of normal regulatory due diligence Neil Davidson CBE will be appointed as Non- Executive Chairman on 1 January 2018. Adam Reynolds, the current Non-Executive Chairman will

    Optibiotix Health Plc

    Optibiotix Health PLC on Kelloggs’ Sugar Levels Cut

    Following the announcement today from Kelloggs to cut the amount of sugar in its three top selling children’s cereals, we caught up with Stephen O’Hara, CEO of OptiBiotix Health PLC (LON:OPTI) for his thoughts:   “We are really